EGFR and prostate cancer: Fenerty et al. have shown that addition of cetuximab to EGFR+, BRCA-mutated prostate cancer cell line 22RV1 or BRCA-wildtype cell line DU145 treated with olaparib increases Antibody Dependent Cell-mediated Cytotoxicity by natural killer cell lysis up to 2.8-fold resp.